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Dyschromatosis symmetrica hereditaria (DSH) (also called “reticulate acropigmentation of Dohi”) is a pigmentary
genodermatosis of autosomal dominant inheritance characterized by a mixture of hyperpigmented and hypopigmented
macules distributed on the dorsal aspects of the hands and feet. To determine the gene responsible for this disease,
we performed a genomewide search in three families with DSH and mapped the DSH locus to chromosome 1q21.3.
The mutations involved in causing DSH have been identified in the gene that encodes double-stranded RNA-specific
adenosine deaminase (DSRAD) as the disease gene.
Dyschromatosis symmetrica hereditaria (DSH [MIM
127400]) (also called “reticulate acropigmentation of
Dohi”) was first described by Toyama (1910, 1929) and
has been reported mainly in Japan, although it occurs in
families of every ethnic origin all over the world (Oyama
et al. 1999). Patients with DSH have pinpoint, pea-sized
hyperpigmented and hypopigmented macules on the back
of their hands and the tops of their feet (fig. 1). The face
is spared, apart from a few scattered small discrete, pig-
mented macules. These abnormalities are otherwise
asymptomatic and do not affect the general health of the
patient. The prevalence of DSH in the population of Japan
is estimated to be ∼1.5 per 100,000. DSH generally shows
an autosomal dominant pattern of inheritance, with high
penetrance, but some patients with sporadic DSH have
been reported. When similar skin lesions occur all over
the body, the disease is discriminated from DSH and is
named “dyschromatosis universalis hereditaria” (DUH
[MIM 127500]). The clinical features of DSH and DUH
are quite distinct and have not been found in the same
pedigrees. Although clinical and morphological investi-
gations of DSH and DUH have been reported, the cause
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and the pathogenesis of the diseases, as well as the patho-
logical gene(s), have not yet been clarified. Until now, the
DSH gene was hypothesized to be located on chromosome
9, because of another family with DSH and idiopathic
torsion dystonia (the gene responsible for the latter disease
is localized on chromosome 9) (Patrizi et al. 1994), but
our early analyses of three Japanese families with DSH
(as shown in fig. 2A–C) excluded chromosome 9 as a
possibility (Kono et al. 2000).
We then tried an entire genomewide scan, using 343
microsatellite markers for linkage analysis in the three
families with DSH (41 affected and 47 unaffected in-
dividuals, as shown in fig. 2A–C), using the method de-
tailed elsewhere (Kono et al. 2000). In brief, genotyping
errors or misspecified relationships within the pedigrees
were checked by the PedCheck software package. DNA
fragment–length analysis on PCR products of microsat-
ellite markers from the Linkage Mapping Set (Perkin
Elmer) was performed, using a Macintosh Centris 650
(Apple Japan) personal computer, with 672 Genescan
software and Genotype, version 1.1 (both Perkin Elmer
products), as described in the manufacturer’s manuals.
The allele size of each marker was rounded, using the
GAS package, version 2.0 (as found on the Oxford Uni-
versity Web site). Calculations for linkage analysis were
performed with the FASTLINK software package, ver-
sion 4.0. (Lathrop et al. 1984; Cottingham et al. 1993;
Schaffer et al. 1994), under an assumed genetic model as
follows: autosomal dominant, gene frequency of 0.0001,
marker-allele frequency set to be equal, complete pene-
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Figure 1 Small hyperpigmented and hypopigmented macules on the dorsal aspects of the hands and feet. Upper, Sixty-year-old female. Lower,
Forty-year-old male.
trance, zero phenocopy rate, and no sex difference. Two-
point LOD scores were calculated with the MLINK mod-
ule in the FASTLINK software package. Kosambi map
function was used to convert the recombination fractions
to map distances. Haplotype analyses were performed us-
ing the SimWalk2 software. The study was approved by
the ethics committee of Nagoya University School of
Medicine.
In a genomewide scan for linkage analysis of three
pedigrees, we obtained cumulative LOD scores 13.0
with satellite markers D1S502, D1S252, D1S498, and
D1S484 in chromosome 1q (table 1; fig. 3). To determine
Figure 2 Pedigrees and haplotypes. A, Pedigree 1. B, Pedigree 2. C, Pedigree 3. D, Pedigree 4. Affected and unaffected individuals are
represented by the blackened and unblackened symbols, respectively. An asterisk (*) indicates individuals who provided blood. Single asterisk
(*) and double asterisk (**) indicate members in pedigrees 1, 2, and 3 who were utilized for linkage analysis. E, Haplotype analysis. The shared
disease-associated haplotype is colored.
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Table 1
Cumulative Two-Point LOD Scores
MARKER
LOD AT v p
Zmax vmax0 .05 .1 .15 .2 .25 .3 .35 .4 .45 .5
D1S424  .17 1.15 1.51 1.59 1.51 1.30 1.01 .66 .29 0 1.59 .20
D1S206  1.21 .56 1.29 1.59 1.64 1.51 1.25 .90 .48 0 1.64 .25
D1S502  3.81 4.88 5.02 4.75 4.23 3.51 2.65 1.68 .71 0 5.02 .15
D1S252  5.46 5.96 5.78 5.29 4.61 3.77 2.82 1.79 .78 0 5.96 .10
D1S498  4.49 4.43 4.09 3.62 3.05 2.42 1.75 1.06 .45 0 4.49 .05
D1S484  1.80 2.99 3.34 3.31 3.05 2.62 2.07 1.42 .71 0 3.34 .15
D1S196  .76 .46 .99 1.21 1.25 1.17 .98 .72 .40 0 1.25 .25
D1S218  7.17 4.03 2.40 1.41 .77 .36 .11 .02 .05 0 .05 .45
Figure 3 Genetic map position for microsatellite markers. A,
Marker used in the linkage analyses, as shown in table 1. B, Markers
used in the haplotype analyses, as shown in figure 2E. cMp Genetic
distance. D1S468 and D1S423 are the nearest markers to the telomeres
of the p and the q arms, respectively.
a smaller interval containing the DSH locus, haplotype
analysis was performed, and the results suggested that
the gene responsible for DSH lies between D1S2715 and
D1S2777 (figs. 2E and 3). To further refine the locali-
zation, we identified novel SNPs and integrated the ge-
netic and physical maps of the region. The final DSH
genetic interval, of ∼500 kb, was bound proximally by
the IL6R gene and distally by the KCNN3 gene, at chro-
mosome 1q21.3. Between those two genes, seven genes
are mapped on the Entrez Genome Map View, NCBI Web
site: namely, NICE-5, cholinergic receptor, double-strand
RNA-specific adenosine deaminase (DSRAD), and four
hypothetical proteins (LOC126669, LOC126668,
LOC343053, and LOC343054).
To detect pathological mutations in the seven candi-
date genes, four affected individuals from each of pedi-
grees 1–3 and pedigree 4 (a fourth family with DSH added
to the study, with 10 affected and 14 unaffected indi-
viduals) were screened by single-strand conformational
polymorphism analysis (SSCP), which revealed mutant
heteroduplexes made by hybridizing PCR fragments of
the DSRAD gene. Every patient in each pedigree showed
the mutant SSCP pattern of exons 2, 10, 10, and 15 in
pedigrees 1, 2, 3, and 4, respectively. Direct sequence
analysis of the PCR products showed that they were
heterozygous for mutations of Arg474STOP (CGAr
TGA), Leu923Pro (CTCrCCC), Lys952STOP (AAAr
TAA), and Phe1165Ser (TTTrTCT) in pedigrees 1, 2,
3, and 4, respectively (fig. 4). None of those four mu-
tations were found in the blood samples of any of the
55 unaffected individuals in any of the four pedigrees
or in the 116 unrelated, normally pigmented Japanese
adults who were surveyed. Thus, we concluded that
those four mutations are not polymorphic but are the
pathologic ones that cause the disease.
DSRAD is composed of 1,226 amino acid residues,
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Figure 4 Mutations of the DSRAD gene found in patients with DSH. Antisense sequences are shown for pedigrees 1 and 2. L923P and
K952X are located in the deaminase domain (red box). N p N-terminal; C p C-terminal.
with a calculated molecular mass of 139 kDa (O’Connell
et al. 1995). It catalyzes the deamination of adenosine
to inosine in double-stranded RNA substrates (Bass and
Weintraub 1988; Wagner et al. 1989), which results in
the creation of alternative splicing sites (Rueter et al.
1999) or alterations of codons and thus leads to func-
tional changes in proteins. DSRAD is expressed ubiqui-
tously (O’Connell et al. 1995), but only three target genes
for DSRAD—including ionotropic glutamate receptor
(Higuchi et al. 1993; Lomeli et al. 1994), the serotonin
receptor 2C subtype in the brain (Burns et al. 1997),
and hepatitis delta virus antigen in the liver (Polson et
al. 1996)—are known. Recently, it was reported that
DSRAD expression was increased in the spleen, thymus,
and peripheral lymphocytes of endotoxin-treated mice
(Yang et al. 2003). The target genes and the induction
of the enzyme in lymphocytes seem not to be involved
in the pathogenesis of DSH.
Since the DSRAD gene has 15 exons, and since three
copies of the dsRNA-binding domains and the putative
deaminase domain are reported to be located in exons
2–7 and 9–14, respectively (Wang et al. 1995), it is un-
derstandable that truncated proteins with no functional
activity would be synthesized from genes with a nonsense
mutation in exon 2 or in exon 10, as found in pedigrees
1 and 3, respectively.
Since the amino acid residue at 923 in exon 10 is also
located in the putative deaminase domain, and since the
4–amino acid sequence containing it is absolutely con-
served among all 11 species, as shown in figure 5A, the
leucine at 923 is suspected to play an important role in
the conformation of the catalytic site of the enzyme, and
the mutation of Leu923Pro probably compromises en-
zyme activity. On the other hand, the missense mutation
at 1165 in exon 15 is a little bit difficult to explain,
because exon 15 is not involved in the catalytic domain.
Phe1165 is supposed to contribute to the structure of
the enzyme, an expectation supported by evidence that
Phe1165 is conserved among all available sequences (fig.
5B); therefore, its mutation may induce an unstable ter-
tiary structure of the protein that results in defective
activity.
Heterozygosity for the Dsrad knockout causes embry-
onic lethality in mice (Wang et al. 2000). In contrast,
patients with DSH have a good prognosis, with only the
dyschromatosis. The prognostic difference between the
two species may depend on differences between them.
The reason the skin lesions are localized specifically on
the backs of the hands and on the tops of the feet is
difficult to explain pathogenetically, since DSRAD is
ubiquitously expressed all over the skin. In the case of
piebaldism—an autosomal dominant disease resulting
from mutations in the c-KIT proto-oncogene (Fleisch-
man et al. 1991; Giebel and Spritz 1991)—white patches
on the forehead, chest, abdomen, and extremities are
induced by the reduced activity of the c-kit receptor,
698 Am. J. Hum. Genet. 73:693–699, 2003
Figure 5 Amino acid alignment of various species around the two missense mutations. Human DSRAD amino acid residues 901–940
(A) and 1151–1190 (B) are shown aligned to known DSRAD orthologues. Residues L, at 923, and F, at 1165, are conserved in all species
compared in the figure. Residues conserved among all available sequences and among all mammalian orthologues are shown with red or yellow
background, respectively. All data were cited from GenBank.
which is required for the migration of melanocyte pre-
cursors throughout the skin during the early fetal period
(Nishikawa et al. 1991). Similarly, we speculate that,
when melanoblasts migrate from the neural crest to the
skin during development, a greater reduction in DSRAD
activity might occur at anatomic sites most distant from
the neural crest. The failure of correct RNA editing may
induce the differentiation of melanoblasts to hyperactive
or hypoactive melanocytes, then colonizing in an irregu-
lar distribution in the skin lesions.
During the preparation of this manuscript, the locus
for DSH was reported, by Zhang et al. (2003), to be at
chromosome 1q11-1q21 and, by Xing et al. (2003), to
be at chromosome 6q24.2-q25.2. The patients of Xing
et al. (2003) showed dyschromatosis over almost their
entire bodies, which suggests that they have DUH. If so,
there is no contradiction between the two studies; that
is, the DSH gene is located on chromosome 1, whereas
the DUH gene is located on chromosome 6.
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